News | August 03, 2025
Beta-HPV can directly cause skin cancer in immunocompromised people
cSCC is one of the most common cancers in the U.S. and globally
cSCC is one of the most common cancers in the U.S. and globally
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Plans underway to expand screening capacity by 50% for greater accessibility
JCI accreditation is recognized globally
Harnessing advanced data analysis for early detection, prevention and better outcomes
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Subscribe To Our Newsletter & Stay Updated
